| Schedule of Reconciles Segment Direct Profit or Loss |
The following table reconciles segment direct profit or loss to the Company’s consolidated results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
(in thousands) |
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
QTORIN rapamycin for microcystic LM |
$ |
1,103 |
|
|
$ |
651 |
|
|
$ |
3,492 |
|
|
$ |
1,078 |
|
QTORIN rapamycin for microcystic LM - Government grant income |
|
(53 |
) |
|
|
(14 |
) |
|
|
(392 |
) |
|
|
(14 |
) |
QTORIN rapamycin for cutaneous VM |
|
827 |
|
|
|
73 |
|
|
|
1,527 |
|
|
|
73 |
|
QTORIN CMC |
|
2,265 |
|
|
|
847 |
|
|
|
4,554 |
|
|
|
1,000 |
|
Non-program specific and unallocated research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
|
1,658 |
|
|
|
1,021 |
|
|
|
4,481 |
|
|
|
2,373 |
|
Consultants |
|
414 |
|
|
|
355 |
|
|
|
1,046 |
|
|
|
705 |
|
Other |
|
314 |
|
|
|
249 |
|
|
|
1,012 |
|
|
|
393 |
|
Total research and development |
$ |
6,528 |
|
|
$ |
3,182 |
|
|
$ |
15,720 |
|
|
$ |
5,608 |
|
General and administrative: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
$ |
2,151 |
|
|
$ |
682 |
|
|
$ |
5,348 |
|
|
$ |
1,439 |
|
Consultants |
|
587 |
|
|
|
908 |
|
|
|
2,497 |
|
|
|
2,186 |
|
Other |
|
911 |
|
|
|
290 |
|
|
|
3,733 |
|
|
|
496 |
|
Total general and administrative |
$ |
3,649 |
|
|
$ |
1,880 |
|
|
$ |
11,578 |
|
|
$ |
4,121 |
|
Loss from operations |
$ |
(10,177 |
) |
|
$ |
(5,062 |
) |
|
$ |
(27,298 |
) |
|
$ |
(9,729 |
) |
|